Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 553

1.

Pharmacokinetics and pharmacodynamics of intravenous PEGylated recombinant mammalian urate oxidase in patients with refractory gout.

Sundy JS, Ganson NJ, Kelly SJ, Scarlett EL, Rehrig CD, Huang W, Hershfield MS.

Arthritis Rheum. 2007 Mar;56(3):1021-8. Erratum in: Arthritis Rheum. 2007 Apr;56(4):1370.

3.

Reduction of plasma urate levels following treatment with multiple doses of pegloticase (polyethylene glycol-conjugated uricase) in patients with treatment-failure gout: results of a phase II randomized study.

Sundy JS, Becker MA, Baraf HS, Barkhuizen A, Moreland LW, Huang W, Waltrip RW 2nd, Maroli AN, Horowitz Z; Pegloticase Phase 2 Study Investigators.

Arthritis Rheum. 2008 Sep;58(9):2882-91. doi: 10.1002/art.23810.

4.

Induced and pre-existing anti-polyethylene glycol antibody in a trial of every 3-week dosing of pegloticase for refractory gout, including in organ transplant recipients.

Hershfield MS, Ganson NJ, Kelly SJ, Scarlett EL, Jaggers DA, Sundy JS.

Arthritis Res Ther. 2014 Mar 7;16(2):R63. doi: 10.1186/ar4500.

5.

Population pharmacokinetic and pharmacodynamic analysis of pegloticase in subjects with hyperuricemia and treatment-failure gout.

Yue CS, Huang W, Alton M, Maroli AN, Waltrip RW, Wright D, Marco MD.

J Clin Pharmacol. 2008 Jun;48(6):708-18. doi: 10.1177/0091270008317589. Epub 2008 Apr 16.

PMID:
18420531
6.

Pegloticase, a polyethylene glycol conjugate of uricase for the potential intravenous treatment of gout.

Biggers K, Scheinfeld N.

Curr Opin Investig Drugs. 2008 Apr;9(4):422-9. Review.

PMID:
18393109
7.

Pegloticase: a novel agent for treatment-refractory gout.

Shannon JA, Cole SW.

Ann Pharmacother. 2012 Mar;46(3):368-76. doi: 10.1345/aph.1Q593. Epub 2012 Mar 6. Review.

PMID:
22395256
8.

Use of polyethylene glycol-modified uricase (PEG-uricase) to treat hyperuricemia in a patient with non-Hodgkin lymphoma.

Chua CC, Greenberg ML, Viau AT, Nucci M, Brenckman WD Jr, Hershfield MS.

Ann Intern Med. 1988 Jul 15;109(2):114-7.

PMID:
3289428
9.

Pharmacokinetics and pharmacodynamics of pegloticase in patients with end-stage renal failure receiving hemodialysis.

Bleyer AJ, Wright D, Alcorn H.

Clin Nephrol. 2015 May;83(5):286-92. doi: 10.5414/CN108481.

PMID:
25816806
10.

Pharmacodynamic analysis of intravenous recombinant urate oxidase using an indirect pharmacological response model in healthy subjects.

Cai NF, Cheng ZN, Zi Y, Luo X, Guo X, Liu Z, Zheng LY.

Acta Pharmacol Sin. 2014 Nov;35(11):1447-52. doi: 10.1038/aps.2014.81. Epub 2014 Oct 6.

11.

Infusion-related reactions with pegloticase, a recombinant uricase for the treatment of chronic gout refractory to conventional therapy.

Baraf HS, Yood RA, Ottery FD, Sundy JS, Becker MA.

J Clin Rheumatol. 2014 Dec;20(8):427-32. doi: 10.1097/RHU.0000000000000200. Review.

12.

Diabetes insipidus in uricase-deficient mice: a model for evaluating therapy with poly(ethylene glycol)-modified uricase.

Kelly SJ, Delnomdedieu M, Oliverio MI, Williams LD, Saifer MG, Sherman MR, Coffman TM, Johnson GA, Hershfield MS.

J Am Soc Nephrol. 2001 May;12(5):1001-9.

13.

Characterization, efficacy, pharmacokinetics, and biodistribution of 5kDa mPEG modified tetrameric canine uricase variant.

Zhang C, Fan K, Luo H, Ma X, Liu R, Yang L, Hu C, Chen Z, Min Z, Wei D.

Int J Pharm. 2012 Jul 1;430(1-2):307-17. doi: 10.1016/j.ijpharm.2012.03.057. Epub 2012 Apr 5.

PMID:
22503989
14.

Uricase formulated with polyethylene glycol (uricase-PEG 20): biochemical rationale and preclinical studies.

Bomalaski JS, Holtsberg FW, Ensor CM, Clark MA.

J Rheumatol. 2002 Sep;29(9):1942-9.

PMID:
12233890
15.

PEG-uricase in the management of treatment-resistant gout and hyperuricemia.

Sherman MR, Saifer MG, Perez-Ruiz F.

Adv Drug Deliv Rev. 2008 Jan 3;60(1):59-68. Epub 2007 Aug 14. Review.

PMID:
17826865
16.

Efficacy and tolerability of pegloticase for the treatment of chronic gout in patients refractory to conventional treatment: two randomized controlled trials.

Sundy JS, Baraf HS, Yood RA, Edwards NL, Gutierrez-Urena SR, Treadwell EL, Vázquez-Mellado J, White WB, Lipsky PE, Horowitz Z, Huang W, Maroli AN, Waltrip RW 2nd, Hamburger SA, Becker MA.

JAMA. 2011 Aug 17;306(7):711-20. doi: 10.1001/jama.2011.1169.

PMID:
21846852
17.

Pegloticase for treating refractory chronic gout.

George RL Jr, Sundy JS.

Drugs Today (Barc). 2012 Jul;48(7):441-9. doi: 10.1358/dot.2012.48.7.1813475. Review.

PMID:
22844655
18.

Efficacy of allopurinol and benzbromarone for the control of hyperuricaemia. A pathogenic approach to the treatment of primary chronic gout.

Perez-Ruiz F, Alonso-Ruiz A, Calabozo M, Herrero-Beites A, García-Erauskin G, Ruiz-Lucea E.

Ann Rheum Dis. 1998 Sep;57(9):545-9.

19.

Effects of febuxostat versus allopurinol and placebo in reducing serum urate in subjects with hyperuricemia and gout: a 28-week, phase III, randomized, double-blind, parallel-group trial.

Schumacher HR Jr, Becker MA, Wortmann RL, Macdonald PA, Hunt B, Streit J, Lademacher C, Joseph-Ridge N.

Arthritis Rheum. 2008 Nov 15;59(11):1540-8. doi: 10.1002/art.24209.

20.

PEG-ing down (and preventing?) the cause of pegloticase failure.

Abeles AM.

Arthritis Res Ther. 2014 May 30;16(3):112. doi: 10.1186/ar4572.

Supplemental Content

Support Center